Assessment of Confirmed Clinical Hypersensitivity to Rituximab in Patients Affected with B-Cell Neoplasia

Table 1

12-step desensitization protocol.

For a patient with a BSA of 1.8 m^2 and rituximab target dose of 375 mg/m^2
Target dose		675 mg
Volume per solution		250 mL
Infusion final ratio (mL/hr)		80 mL/hr
Final concentration (dose/volume)		2,7
3 solutions		Total dose/solution			Volume
Solution 1	1/100		1,5 mg		50 mL
Solution 2	1//10		15 mg		50 mL
Solution 3	(Standard)		669 mg		250 mL
Steps	Solution	Infusion mL/hr	Time (min)	Vol/step	Dose/step	Cumulative dose
1	1	2	15	0,5	0,015	0,015
2		5	15	1,25	0,038	0,05
3		10	15	2,5	0,08	0,13
4		20	15	5	0,15	0,28
5	2	5	15	1,25	0,38	0,65
6		10	15	2,5	0,75	1,40
7		20	15	5	1,50	2,90
8		40	15	10	3,00	5,90
9	3	10	15	2,5	6,69	12,59
10		20	15	5	13,38	25,98
11		40	15	10	26,76	52,74
12		80	174,375	232,5	622,26	675,00
Total time			339,38 min		Total dose	675 mg
			5,66 hours